Black Titan (BTTC) AI Stock Analysis

• Market Cap: $15.72M
• Dividend Yield: N/A
• Average Volume (3M): 508.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: N/A
• EPS Growth: 60.78%
• Country: US
• Employees: 2
• Sector: General
• Sector Strength: N/A
• Industry: Asset Management
• EPS (TTM): N/A
• Shares Outstanding: 9,086,610
• 10 Day Avg. Volume: 493,518
• 30 Day Avg. Volume: 508,156
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.22K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -9.42K
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 34 Underperform
• Price Target: ―

Titan Pharmaceuticals' stock faces considerable financial performance issues, with declining revenues, negative cash flows, and operational inefficiencies posing significant challenges. Technical analysis indicates a lack of clear momentum, while valuation metrics are unattractive due to negative earnings. The lack of recent earnings call data or relevant corporate events leaves these negative factors largely unchecked, resulting in a low overall stock score.

Black Titan Business Overview & Revenue Model

Company Description

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

How the Company Makes Money

Titan Pharmaceuticals generates revenue primarily through the commercialization of its flagship product, Probuphine. The company earns income from product sales, licensing agreements, and royalties. Probuphine, as a treatment for opioid dependence, is sold to healthcare providers and distributed through specialty pharmaceutical distribution channels. Additionally, Titan engages in strategic partnerships and collaborations with other pharmaceutical companies, which can result in upfront payments, milestone payments, and ongoing royalty streams based on product sales.

Black Titan Financial Statement Overview

Summary

Titan Pharmaceuticals faces significant financial challenges, marked by declining revenues, persistent losses, and negative cash flows. The company benefits from having no debt, but operational inefficiencies and diminishing asset value overshadow this advantage. Reliance on external financing is a risk, and efforts to stabilize revenue and improve profitability are crucial.

Income Statement

Titan Pharmaceuticals demonstrates a consistent decline in revenue over recent years, with the latest year showing no revenue generation. Gross profit margins have deteriorated, and the company continues to report substantial net losses, indicating ongoing challenges in achieving profitability. The negative EBIT and EBITDA margins reflect operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a strong equity position with no current debt, resulting in a zero debt-to-equity ratio. However, the significant decline in total assets and stockholders' equity over time raises concerns about long-term financial health. The equity ratio remains relatively high, but the shrinking asset base could pose risks if the trend continues.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow in recent years, reflecting difficulties in generating cash from operations. Although there has been a slight improvement in free cash flow year-over-year, the company is still heavily reliant on financing activities to cover its cash requirements.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	2.68M	2.12M	2.08M	2.40M	1.53M
Gross Profit	0.00	884.93K	686.84K	464.11K	550.46K	1.22M
EBITDA	-2.04M	286.56K	237.23K	107.34K	27.11K	-8.55M
Net Income	-1.80B	209.91K	153.23K	11.69K	-86.56K	-8.78M
Balance Sheet
Total Assets	23.23B	2.72M	2.22M	1.10M	1.34M	7.99M
Cash, Cash Equivalents and Short-Term Investments	74.09M	575.11K	371.96K	3.35K	6.96K	6.33M
Total Debt	825.70M	302.15K	294.14K	669.51K	836.09K	299.00K
Total Liabilities	3.34B	1.77M	1.21M	1.34M	1.60M	2.86M
Stockholders Equity	19.89B	954.29K	1.00M	-242.48K	-255.13K	5.14M
Cash Flow
Free Cash Flow	-645.61M	270.79K	190.03K	308.48K	-411.00	-7.92M
Operating Cash Flow	-645.61M	394.22K	191.55K	308.48K	-252.00	-7.90M
Investing Cash Flow	0.00	-123.42K	-1.53K	0.00	-159.00	-23.00K
Financing Cash Flow	621.76M	-417.20K	556.46K	-302.84K	-25.63K	8.84M

Black Titan Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTTC, the sentiment is Negative. The current price of 1.69 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.88, and below the 200-day MA of 4.20, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 38.09 is Neutral, neither overbought nor oversold. The STOCH value of 21.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTTC.

Black Titan Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MLCI	61 Neutral	$6.81M	-4.16	-25.88%	1.07%	66.65%	-1497.99%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
BCG	55 Neutral	$43.66M	67.96	5.87%	―	-37.08%	―
BENF	42 Neutral	$74.36M	-0.06	―	―	-33.98%	94.83%
CWD	42 Neutral	$9.60M	-0.07	-1438.14%	―	-62.09%	-99.89%
ATON	40 Underperform	$6.94M	-0.01	―	―	―	―
BTTC	34 Underperform	$15.72M	-0.64	-109.09%	―	―	60.78%

Black Titan Corporate Events

Black Titan Appoints New Co-CEO Amid Strategic Expansion

On November 10, 2025, Black Titan Corporation appointed Czhang Lin as Co-Chief Executive Officer, enhancing its leadership team to drive strategic expansion into the digital asset and blockchain sectors. Mr. Lin, with extensive experience in cryptocurrency and blockchain, will lead the company’s crypto strategy, focusing on investments and fintech-related mergers, aiming to unlock long-term value for shareholders. Additionally, the company settled a warrant repurchase with Armistice Capital Master Fund Ltd. on October 30, 2025, involving a $1 million cash payment and $2 million in restricted shares, following a business combination with Titan Pharmaceuticals, Inc.

Black Titan Completes Major Acquisition and Secures $5.5 Million Investment

On October 1, 2025, Black Titan Corporation completed a significant business combination by acquiring Titan Pharmaceuticals and TalenTec, making them wholly owned subsidiaries. This strategic move, approved by Titan’s stockholders on August 26, 2025, involved exchanging shares and is expected to enhance Black Titan’s market position in the pharmaceutical and technology sectors. Additionally, Black Titan issued a Drawdown Notice for $5.5 million in Series A Preferred Shares, strengthening its financial position and providing flexibility for future growth.

Black Titan Corporation Announces Strategic Crypto Initiatives

On October 6, 2025, Black Titan Corporation announced its intention to explore long-term strategic initiatives in the cryptocurrency sector. The company aims to leverage debt, equity, and cash flow to build its crypto holdings, capitalizing on emerging opportunities in digital currencies. This move is aligned with the optimistic stance of the new Trump administration and potential embracement by major financial institutions, marking a strategic expansion in Black Titan’s portfolio.